BiomX Q4 2025 Earnings Report

BiomX EPS Results

• Actual EPS: $6.99
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

BiomX Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BiomX Announcement Details

• Quarter: Q4 2025
• Date: 2/19/2026
• Time: After Market Closes
• Conference Call Date: Thursday, February 19, 2026
• Conference Call Time: 7:00AM ET

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis. Preclinical studies have demonstrated the ability of BiomX’s phage preparations to reduce targeted bacterial populations implicated in inflammation and disease progression. Advanced product characterization and manufacturing processes support both oral and topical delivery formats, positioning BiomX to advance multiple candidates through regulatory pathways.

Founded in 2016 as a spin-out from MIGAL – Galilee Research Institute, BiomX is headquartered in Rehovot, Israel, with a U.S. presence in Cambridge, Massachusetts. The company conducts clinical trials across North America and Europe, collaborating with academic medical centers and contract research organizations. Since its initial public listing on the NYSE American exchange under the ticker PHGE, BiomX has expanded its leadership team to include executives with deep expertise in phage biology, clinical development and biomanufacturing. The company’s research and development efforts are overseen by CEO Eliora Ron, who guides strategic initiatives to translate microbiome science into targeted, next-generation therapies.